 Connection
David Mery to Cell Line, Tumor
This is a "connection" page, showing publications David Mery has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.108 |
|
|
|
-
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
Score: 0.042
-
Ord??ez PE, Mery DE, Sharma KK, Nemu S, Reynolds WF, Enriquez RG, Burns DC, Malag?n O, Jones DE, Guzman ML, Compadre CM. Synthesis, Crystallography, and Anti-Leukemic Activity of the Amino Adducts of Dehydroleucodine. Molecules. 2020 Oct 20; 25(20).
Score: 0.034
-
Bystrom LM, Bezerra DP, Hsu HT, Zong H, Lara-Mart?nez LA, De Leon JP, Emmanuel M, M?ry D, Gardenghi S, Hassane D, Neto CC, Cunningham-Rundles S, Becker MW, Rivella S, Guzman ML. Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells. Blood Adv. 2019 11 12; 3(21):3261-3265.
Score: 0.032
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|